Previous close | 4.0000 |
Open | 3.5000 |
Bid | 4.3000 |
Ask | 4.5000 |
Strike | 15.00 |
Expiry date | 2025-01-17 |
Day's range | 3.5000 - 4.4000 |
Contract range | N/A |
Volume | |
Open interest | 5.48k |
SAN CARLOS, Calif., March 22, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that on March 22, 2024 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 97,700 shares of Iovance’s common stock to twenty new, non-ex
Unless you borrow money to invest, the potential losses are limited. On the other hand, if you find a high quality...
In this article, we will take a detailed look at Billionaire Paul Tudor Jones and Insiders Love These 10 Stocks. For a quick overview of such stocks, read our article Billionaire Paul Tudor Jones and Insiders Love These 5 Stocks. In an interview given to the Palm Beach Civic Association in January 2024, billionaire Paul Tudor Jones said that […]